Response to IncobotulinumtoxinA After Resistance to OnabotulinumtoxinA and RimabotulinumtoxinB (P7.061)

CONCLUSIONS:Switching to incobotulinumtoxinA after secondary resistance to onabotulinumtoxinA and rimabotulinumtoxinB may be a viable treatment option in dystonia.Study Supported by:National Institutes of Health- National Institutes of Neurological Diseases and Stroke and the Dystonia Medical Research FoundationDisclosure: Dr. Ramos has received personal compensation for activities with the National Inistitutes of Health as an employee, and the Dystonia Medical Research Foundation. Dr. Karp has nothing to disclose. Dr. Lungu has nothing to disclose. Dr. Alter has nothing to disclose. Dr. Hallett has received personal compensation for activities with Neurotoxin Institute, Cambridge University Press, Oxford University Press, Wiley-Blackwell, Springer, Wolters Kluwer, and Elsevier. Dr. Hallett has received royalty payments from the National Institutes of Health. Dr. Hallett's institute has received research support from BCN Peptides and Manhattan Pharmaceuticals.

Source: Neurology - April 9, 2014 Category: Neurology Authors: Ramos, V., Karp, B., Lungu, C., Alter, K., Hallett, M. Tags: Movement Disorders: Dystonia Treatment Source Type: research